301 related articles for article (PubMed ID: 17693643)
1. The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma.
Teng HW; Chen PM; Yang YH; Gau JP
Jpn J Clin Oncol; 2007 Aug; 37(8):609-14. PubMed ID: 17693643
[TBL] [Abstract][Full Text] [Related]
2. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors affecting survival in multiple myeloma].
Tornóczky J; Tóth A; Sziládi E; Hoffmann E; Liszátz M
Orv Hetil; 1990 Aug; 131(31):1679-84. PubMed ID: 2205822
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].
Spicka I; Cieslar P; Procházka B; Jirsa M; Chrz M; Gregora E; Klener P
Cas Lek Cesk; 2000 Apr; 139(7):208-12. PubMed ID: 10916207
[TBL] [Abstract][Full Text] [Related]
5. Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.
Rossi F; Petrucci MT; Guffanti A; Marcheselli L; Rossi D; Callea V; Vincenzo F; De Muro M; Baraldi A; Villani O; Musto P; Bacigalupo A; Gaidano G; Avvisati G; Goldaniga M; Depaoli L; Baldini L
Clin Cancer Res; 2009 Jul; 15(13):4439-45. PubMed ID: 19509142
[TBL] [Abstract][Full Text] [Related]
6. [Multiple myeloma--diagnosis, prognostic factors and treatment].
Kitani T
Rinsho Ketsueki; 1995 May; 36(5):471-9. PubMed ID: 7783353
[TBL] [Abstract][Full Text] [Related]
7. Causes of isolated prolonged activated partial thromboplastin time in an acute care general hospital.
Chng WJ; Sum C; Kuperan P
Singapore Med J; 2005 Sep; 46(9):450-6. PubMed ID: 16123828
[TBL] [Abstract][Full Text] [Related]
8. Prolonged prothrombin time correlates with serum monoclonal protein concentration in patients with plasma cell dyscrasia.
Pandey S; Post SR; Alapat DV; Smock KJ; Post GR
Int J Lab Hematol; 2013 Aug; 35(4):421-7. PubMed ID: 23217011
[TBL] [Abstract][Full Text] [Related]
9. Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma.
Huang H; Li H; Li D
Blood Coagul Fibrinolysis; 2015 Jul; 26(5):555-9. PubMed ID: 25828972
[TBL] [Abstract][Full Text] [Related]
10. Measurement of prothrombin time and activated partial thromboplastin time in citrated whole blood samples from clinically ill dogs following storage.
Maunder CL; Costa M; Cue SM; Crawford EM; Papasouliotis K; Murphy KF
J Small Anim Pract; 2012 Sep; 53(9):531-5. PubMed ID: 22860986
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
Elice F; Fink L; Tricot G; Barlogie B; Zangari M
Br J Haematol; 2006 Aug; 134(4):399-405. PubMed ID: 16882132
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of drawing coagulation samples from heparinized arterial lines.
Templin K; Shively M; Riley J
Am J Crit Care; 1993 Jan; 2(1):88-95. PubMed ID: 8353585
[TBL] [Abstract][Full Text] [Related]
13. Acquired coagulopathy owing to parenteral cefamandole: renal failure as a predisposing factor.
Chang JC
Ann Clin Lab Sci; 1983; 13(5):418-24. PubMed ID: 6638932
[TBL] [Abstract][Full Text] [Related]
14. [Prolonged activated partial thromboplastin time, Quick's time, bleeding time. Diagnostic orientation].
Guillin MC
Rev Prat; 1994 Sep; 44(14):1942-8. PubMed ID: 7939287
[No Abstract] [Full Text] [Related]
15. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
[TBL] [Abstract][Full Text] [Related]
16. Properties of optical data from activated partial thromboplastin time and prothrombin time assays.
Braun PJ; Givens TB; Stead AG; Beck LR; Gooch SA; Swan RJ; Fischer TJ
Thromb Haemost; 1997 Sep; 78(3):1079-87. PubMed ID: 9308757
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
18. Immunological methods in the diagnosis of monoclonal gammopathies. The prognostic impact of the immunological data.
Baldea L; Cucuianu A; Cristea A
Rom J Intern Med; 1999; 37(3):217-25. PubMed ID: 15532300
[TBL] [Abstract][Full Text] [Related]
19. Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma.
Matta GM; Battaglio S; Dibello C; Napoli P; Baldi C; Ciccone G; Coscia M; Boccadoro M; Massaia M
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5348-54. PubMed ID: 17875762
[TBL] [Abstract][Full Text] [Related]
20. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders.
Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
Br J Haematol; 2008 Apr; 141(2):205-11. PubMed ID: 18318761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
